1. Market Research
  2. > Chronic Inflammation - Pipeline Review, H2 2013

Chronic Inflammation - Pipeline Review, H2 2013

  • November 2013
  • -
  • Global Markets Direct
  • -
  • 52 pages

Chronic Inflammation - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Chronic Inflammation - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Chronic Inflammation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Inflammation. Chronic Inflammation - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Chronic Inflammation.
- A review of the Chronic Inflammation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Chronic Inflammation pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Chronic Inflammation.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Chronic Inflammation pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Chronic Inflammation - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Chronic Inflammation Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Chronic Inflammation 8
Chronic Inflammation Therapeutics under Development by Companies 10
Chronic Inflammation Therapeutics under Investigation by Universities/Institutes 12
Early Clinical Stage Products 13
Comparative Analysis 13
Discovery and Pre-Clinical Stage Products 14
Comparative Analysis 14
Chronic Inflammation Therapeutics - Products under Development by Companies 15
Chronic Inflammation Therapeutics - Products under Investigation by Universities/Institutes 16
Companies Involved in Chronic Inflammation Therapeutics Development 17
Italfarmaco S.p.A. 17
Phenex Pharmaceuticals AG 18
Anacor Pharmaceuticals, Inc. 19
Reata Pharmaceuticals, Inc. 20
Dynamis Therapeutics, Inc. 21
Biolink Group AS 22
Dompe Farmaceutici S.p.A. 23
KAEL-GemVax 24
Biocure pharm 25
Chronic Inflammation - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
tertomotide - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
DF-2156A - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
CIF-C/D-3G - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
Retinoid-Acid Receptor Related Orphan Receptor Gamma T Program - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
Tumor Necrosis Factor Receptor 25 Antagonists - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
AN-3485 - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
AIMs For Chronic Inflammation - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
BCP-1071 - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
MCP-1 - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
TACE Inhibitory Protein - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
Anti-Alpha Epsilon Beta-7 - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
VAC-03 - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
DYN-15 - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
Drug For Chronic Inflammation - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
TAT-SNAP-23 - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
N-Acylethanolamine Acid Amidase Inhibitors - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
Chronic Inflammation Therapeutics - Drug Profile Updates 48
Chronic Inflammation Therapeutics - Dormant Products 50
Appendix 51
Methodology 51
Coverage 51
Secondary Research 51
Primary Research 51
Expert Panel Validation 51
Contact Us 52
Disclaimer 52



List of Tables

Number of Products Under Development for Chronic Inflammation, H2 2013 8
Products under Development for Chronic Inflammation - Comparative Analysis, H2 2013 9
Number of Products under Development by Companies, H2 2013 11
Number of Products under Investigation by Universities/Institutes, H2 2013 12
Comparative Analysis by Early Clinical Stage Development, H2 2013 13
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 14
Products under Development by Companies, H2 2013 15
Products under Investigation by Universities/Institutes, H2 2013 16
Italfarmaco S.p.A., H2 2013 17
Phenex Pharmaceuticals AG, H2 2013 18
Anacor Pharmaceuticals, Inc., H2 2013 19
Reata Pharmaceuticals, Inc., H2 2013 20
Dynamis Therapeutics, Inc., H2 2013 21
Biolink Group AS, H2 2013 22
Dompe Farmaceutici S.p.A., H2 2013 23
KAEL-GemVax, H2 2013 24
Biocure pharm, H2 2013 25
Assessment by Monotherapy Products, H2 2013 26
Assessment by Stage and Route of Administration, H2 2013 28
Assessment by Stage and Molecule Type, H2 2013 30
Chronic Inflammation Therapeutics - Drug Profile Updates 48
Chronic Inflammation Therapeutics - Dormant Products 50



List of Figures

Number of Products under Development for Chronic Inflammation, H2 2013 8
Products under Development for Chronic Inflammation - Comparative Analysis, H2 2013 9
Products under Development by Companies, H2 2013 10
Products under Investigation by Universities/Institutes, H2 2013 12
Early Clinical Stage Products, H2 2013 13
Discovery and Pre-Clinical Stage Products, H2 2013 14
Assessment by Monotherapy Products, H2 2013 26
Assessment by Route of Administration, H2 2013 27
Assessment by Stage and Route of Administration, H2 2013 28
Assessment by Molecule Type, H2 2013 29
Assessment by Stage and Molecule Type, H2 2013 30



Companies Mentioned

Italfarmaco S.p.A.
Phenex Pharmaceuticals AG
Anacor Pharmaceuticals, Inc.
Reata Pharmaceuticals, Inc.
Dynamis Therapeutics, Inc.
Biolink Group AS
Dompe Farmaceutici S.p.A.
KAEL-GemVax
Biocure pharm

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.